Andere Sprachen Biotest AG

Aktien

522723

DE0005227235

BIO3

Realtime-Estimate Tradegate Andere Börsenplätze 13:30:00 16.04.2024			% 5 Tage	% 1. Jan.
28.8 ^EUR	0.00%		-1.04%	-8.06%

28.03.	Biotest Aktiengesellschaft berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Biotest Aktiengesellschaft meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Biotest AG increased sales by 32% in the financial year 2023	28.03.
Biotest : Sustainability report Declaration of compliance 2023	28.03.
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Biotest : Invitation / Agenda of Annual General Meeting 2024	26.03.
Biotest : Notes on agenda item 1 - German Version	25.03.
Biotest achieves EBIT forecast for 2023	29.02.
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care	28.02.
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate	14.02.
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	30.01.
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	22.01.
Biotest AG opens 11th plasma collection centre in Germany	18.01.
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	11.01.
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)	12.12.
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation	28.11.
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02.11.
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023	02.11.
Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024	05.10.23
Biotest AG: Increase of the EBIT guidance	05.10.23
Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023	05.10.23
Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG	05.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biotest AG

Aktien

522723

DE0005227235

BIO3

Andere Sprachen

Filter